Table 2 Baseline patient and tumor characteristics
Trastuzumab (n = 33) | Lapatinib (n = 34) | Trastuzumab + Lapatinib (n = 33) | Total (N = 100) | |
|---|---|---|---|---|
Demographics | ||||
Age (years) | ||||
Mean (standard deviation) | 51.1 (10.90) | 50.8 (8.76) | 49.2 (10.47) | 50.4 (10.01) |
Median (range) | 54.0 (21-67) | 52.0 (25-67) | 50.0 (28-66) | 51.5 (21-67) |
<65 years, n (%) | 31 (94) | 32 (94) | 30 (91) | 93 (93) |
≥65 years, n (%) | 2 (6) | 2 (6) | 3 (9) | 7 (7) |
Menopausal status, n (%) | ||||
Postmenopausal | 19 (58) | 19 (56) | 16 (48) | 54 (54) |
Sterile | 5 (15) | 5 (15) | 6 (18) | 16 (16) |
Potential to bear children | 9 (27) | 10 (29) | 11 (33) | 30 (30) |
Race, n (%) | ||||
African American | 8 (24) | 1 (3) | 2 (6) | 11 (11) |
White/Caucasian | 25 (76) | 27 (79) | 29 (88) | 81 (81) |
Other | 0 | 6 (18) | 2 (6) | 8 (8) |
Disease characteristics | ||||
Histology, n (%) | ||||
Adenocarcinoma | 3 (9) | 6 (18) | 1 (3) | 10 (10) |
Medullary | 0 | 0 | 1 (3) | 1 (1) |
Lobular invasive | 0 | 1 (3) | 2 (6) | 3 (3) |
Infiltrating ductal NOS | 26 (79) | 23 (68) | 22 (67) | 71 (71) |
Other | 4 (12) | 4 (12) | 7 (21) | 15 (15) |
Grade, n (%) | ||||
Not assessed | 3 (9) | 3 (9) | 3 (9) | 9 (9) |
Well differentiated | 0 | 3 (9) | 1 (3) | 4 (4) |
Moderately | 10 (30) | 7 (21) | 12 (36) | 29 (29) |
Poorly | 20 (61) | 21 (62) | 17 (52) | 58 (58) |
Hormone receptor status, n (%) | ||||
Positive (ER + and/or PR+) | 15 (45) | 14 (41) | 20 (61) | 49 (49) |
Negative (ER- and PR-) | 18 (55) | 20 (59) | 13 (39) | 51 (51) |
HER2-IHC status, n (%) | ||||
0 | 2 (6) | 0 | 1 (3) | 3 (3) |
1+ | 0 | 0 | 1 (3) | 1 (1) |
2+ | 4 (12) | 3 (9) | 0 | 7 (7) |
3+ | 22 (67) | 26 (76) | 26 (79) | 74 (74) |
Unknown | 5 (15) | 5 (15) | 5 (15) | 5 (15) |
HER2-FISH status, n (%) | ||||
Positive | 27 (82) | 24 (71) | 23 (70) | 74 (74) |
Negative | 0 | 1 (3) | 0 | 1 (1) |
Unknown | 6 (18) | 9 (26) | 10 (30) | 25 (25) |
Tumor size, n (%) | ||||
T2 | 22 (67) | 12 (35) | 22 (67) | 56 (56) |
T3 | 8 (24) | 11 (32) | 6 (18) | 25 (25) |
T4 | 3 (9) | 8 (24) | 5 (15) | 16 (16) |
Tx | 0 | 3 (9) | 0 | 3 (3) |
TNM stage: regional nodes, n (%) | ||||
N0 | 18 (55) | 11 (32) | 13 (39) | 42 (42) |
N1 | 12 (36) | 16 (47) | 14 (42) | 42 (42) |
N2 | 3 (9) | 7 (21) | 6 (18) | 16 (16) |